Breast Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Breast Cancer – Pipeline Review, H2 2016’, provides an overview of the Breast Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Breast Cancer

The report reviews pipeline therapeutics for Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Breast Cancer therapeutics and enlists all their major and minor projects

The report assesses Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Breast Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Breast Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-D Matrix Ltd

3-V Biosciences Inc

3SBio Inc

4SC AG

A&G Pharmaceutical Inc

AB Science SA

AbbVie Inc

AbGenomics International Inc

Acceleron Pharma Inc

Acetylon Pharmaceuticals Inc

Adaptimmune Therapeutics Plc

ADC Therapeutics Sarl

Adgero Biopharmaceuticals Inc

Aduro BioTech Inc

Advanced Accelerator Applications SA

Advanced Cancer Therapeutics

Advanced Proteome Therapeutics Corp

Advantagene Inc

Advaxis Inc

Advenchen Laboratories LLC

Aegis Therapeutics LLC

Aeglea BioTherapeutics Inc

Aerpio Therapeutics Inc

Aeterna Zentaris Inc

Affichem SA

Agenus Inc

Agilvax Inc

Aileron Therapeutics Inc

Alchemia Ltd

Alethia Biotherapeutics Inc

Alissa Pharma

Almac Discovery Ltd

Alteogen Inc

Amarna Therapeutics BV

Ambrx Inc

American Gene Technologies International Inc

Amgen Inc

Ampio Pharmaceuticals Inc

Amplyx Pharmaceuticals Inc

Angion Biomedica Corp

ANP Technologies Inc

AntiCancer Inc

Antigen Express Inc

Antoxis Ltd

Aphios Corp

APIM Therapeutics AS

Aptevo Therapeutics Inc

Aravive Biologics Inc

ARMO Biosciences Inc

Armour Therapeutics Inc

Arno Therapeutics Inc

ArQule Inc

Arrien Pharmaceuticals LLC

Arvinas Inc

Asana BioSciences LLC

Ascentage Pharma Group Corp Ltd

AskAt Inc

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Athenex Inc

ATLAB Pharma SAS

Atossa Genetics Inc

AVEO Pharmaceuticals Inc

Avexxin AS

Azaya Therapeutics Inc

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bavarian Nordic A/S

Bayer AG

BCN Biosciences LLC

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Berg LLC

BerGenBio AS

Beta Pharma Inc

Bexion Pharmaceuticals LLC

BeyondSpring Pharmaceuticals Inc

Bicycle Therapeutics Ltd

Bio-Path Holdings Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 19

Breast Cancer Overview 20

Therapeutics Development 21

Breast Cancer - Therapeutics under Development by Companies 23

Breast Cancer - Therapeutics under Investigation by Universities/Institutes 66

Breast Cancer - Pipeline Products Glance 75

Breast Cancer - Products under Development by Companies 79

Breast Cancer - Products under Investigation by Universities/Institutes 145

Breast Cancer - Companies Involved in Therapeutics Development 160

Breast Cancer - Therapeutics Assessment 617

Drug Profiles 713

Breast Cancer - Dormant Projects 2934

Breast Cancer - Discontinued Products 3000

Breast Cancer - Product Development Milestones 3013

Appendix 3027

List of Tables

List of Tables

Number of Products under Development for Breast Cancer, H2 2016 142

Number of Products under Development for Breast Cancer – Comparative Analysis, H2 2016 143

Number of Products under Development by Companies, H2 2016 145

Number of Products under Development by Companies, H2 2016 (Contd..1) 146

Number of Products under Development by Companies, H2 2016 (Contd..2) 147

Number of Products under Development by Companies, H2 2016 (Contd..3) 148

Number of Products under Development by Companies, H2 2016 (Contd..4) 149

Number of Products under Development by Companies, H2 2016 (Contd..5) 150

Number of Products under Development by Companies, H2 2016 (Contd..6) 151

Number of Products under Development by Companies, H2 2016 (Contd..7) 152

Number of Products under Development by Companies, H2 2016 (Contd..8) 153

Number of Products under Development by Companies, H2 2016 (Contd..9) 154

Number of Products under Development by Companies, H2 2016 (Contd..10) 155

Number of Products under Development by Companies, H2 2016 (Contd..11) 156

Number of Products under Development by Companies, H2 2016 (Contd..12) 157

Number of Products under Development by Companies, H2 2016 (Contd..13) 158

Number of Products under Development by Companies, H2 2016 (Contd..14) 159

Number of Products under Development by Companies, H2 2016 (Contd..15) 160

Number of Products under Development by Companies, H2 2016 (Contd..16) 161

Number of Products under Development by Companies, H2 2016 (Contd..17) 162

Number of Products under Development by Companies, H2 2016 (Contd..18) 163

Number of Products under Development by Companies, H2 2016 (Contd..19) 164

Number of Products under Development by Companies, H2 2016 (Contd..20) 165

Number of Products under Development by Companies, H2 2016 (Contd..21) 166

Number of Products under Development by Companies, H2 2016 (Contd..22) 167

Number of Products under Development by Companies, H2 2016 (Contd..23) 168

Number of Products under Development by Companies, H2 2016 (Contd..24) 169

Number of Products under Development by Companies, H2 2016 (Contd..25) 170

Number of Products under Development by Companies, H2 2016 (Contd..26) 171

Number of Products under Development by Companies, H2 2016 (Contd..27) 172

Number of Products under Development by Companies, H2 2016 (Contd..28) 173

Number of Products under Development by Companies, H2 2016 (Contd..29) 174

Number of Products under Development by Companies, H2 2016 (Contd..30) 175

Number of Products under Development by Companies, H2 2016 (Contd..31) 176

Number of Products under Development by Companies, H2 2016 (Contd..32) 177

Number of Products under Development by Companies, H2 2016 (Contd..33) 178

Number of Products under Development by Companies, H2 2016 (Contd..34) 179

Number of Products under Development by Companies, H2 2016 (Contd..35) 180

Number of Products under Development by Companies, H2 2016 (Contd..36) 181

Number of Products under Development by Companies, H2 2016 (Contd..37) 182

Number of Products under Development by Companies, H2 2016 (Contd..38) 183

Number of Products under Development by Companies, H2 2016 (Contd..39) 184

Number of Products under Development by Companies, H2 2016 (Contd..40) 185

Number of Products under Development by Companies, H2 2016 (Contd..41) 186

Number of Products under Investigation by Universities/Institutes, H2 2016 187

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 188

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 189

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 190

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 191

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 192

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 193

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 194

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 195

Comparative Analysis by Late Stage Development, H2 2016 196

Comparative Analysis by Clinical Stage Development, H2 2016 197

Comparative Analysis by Early Stage Development, H2 2016 198

Comparative Analysis by Unknown Stage Development, H2 2016 199

Products under Development by Companies, H2 2016 200

Products under Development by Companies, H2 2016 (Contd..1) 201

Products under Development by Companies, H2 2016 (Contd..2) 202

Products under Development by Companies, H2 2016 (Contd..3) 203

Products under Development by Companies, H2 2016 (Contd..4) 204

Products under Development by Companies, H2 2016 (Contd..5) 205

Products under Development by Companies, H2 2016 (Contd..6) 206

Products under Development by Companies, H2 2016 (Contd..7) 207

Products under Development by Companies, H2 2016 (Contd..8) 208

Products under Development by Companies, H2 2016 (Contd..9) 209

Products under Development by Companies, H2 2016 (Contd..10) 210

Products under Development by Companies, H2 2016 (Contd..11) 211

Products under Development by Companies, H2 2016 (Contd..12) 212

Products under Development by Companies, H2 2016 (Contd..13) 213

Products under Development by Companies, H2 2016 (Contd..14) 214

Products under Development by Companies, H2 2016 (Contd..15) 215

Products under Development by Companies, H2 2016 (Contd..16) 216

Products under Development by Companies, H2 2016 (Contd..17) 217

Products under Development by Companies, H2 2016 (Contd..18) 218

Products under Development by Companies, H2 2016 (Contd..19) 219

Products under Development by Companies, H2 2016 (Contd..20) 220

Products under Development by Companies, H2 2016 (Contd..21) 221

Products under Development by Companies, H2 2016 (Contd..22) 222

Products under Development by Companies, H2 2016 (Contd..23) 223

Products under Development by Companies, H2 2016 (Contd..24) 224

Products under Development by Companies, H2 2016 (Contd..25) 225

Products under Development by Companies, H2 2016 (Contd..26) 226

Products under Development by Companies, H2 2016 (Contd..27) 227

Products under Development by Companies, H2 2016 (Contd..28) 228

Products under Development by Companies, H2 2016 (Contd..29) 229

Products under Development by Companies, H2 2016 (Contd..30) 230

Products under Development by Companies, H2 2016 (Contd..31) 231

Products under Development by Companies, H2 2016 (Contd..32) 232

Products under Development by Companies, H2 2016 (Contd..33) 233

Products under Development by Companies, H2 2016 (Contd..34) 234

Products under Development by Companies, H2 2016 (Contd..35) 235

Products under Development by Companies, H2 2016 (Contd..36) 236

Products under Development by Companies, H2 2016 (Contd..37) 237

Products under Development by Companies, H2 2016 (Contd..38) 238

Products under Development by Companies, H2 2016 (Contd..39) 239

Products under Development by Companies, H2 2016 (Contd..40) 240

Products under Development by Companies, H2 2016 (Contd..41) 241

Products under Development by Companies, H2 2016 (Contd..42) 242

Products under Development by Companies, H2 2016 (Contd..43) 243

Products under Development by Companies, H2 2016 (Contd..44) 244

Products under Development by Companies, H2 2016 (Contd..45) 245

Products under Development by Companies, H2 2016 (Contd..46) 246

Products under Development by Companies, H2 2016 (Contd..47) 247

Products under Development by Companies, H2 2016 (Contd..48) 248

Products under Development by Companies, H2 2016 (Contd..49) 249

Products under Development by Companies, H2 2016 (Contd..50) 250

Products under Development by Companies, H2 2016 (Contd..51) 251

Products under Development by Companies, H2 2016 (Contd..52) 252

Products under Development by Companies, H2 2016 (Contd..53) 253

Products under Development by Companies, H2 2016 (Contd..54) 254

Products under Development by Companies, H2 2016 (Contd..55) 255

Products under Development by Companies, H2 2016 (Contd..56) 256

Products under Development by Companies, H2 2016 (Contd..57) 257

Products under Development by Companies, H2 2016 (Contd..58) 258

Products under Development by Companies, H2 2016 (Contd..59) 259

Products under Development by Companies, H2 2016 (Contd..60) 260

Products under Development by Companies, H2 2016 (Contd..61) 261

Products under Development by Companies, H2 2016 (Contd..62) 262

Products under Development by Companies, H2 2016 (Contd..63) 263

Products under Development by Companies, H2 2016 (Contd..64) 264

Products under Development by Companies, H2 2016 (Contd..65) 265

Products under Investigation by Universities/Institutes, H2 2016 266

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 267

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 268

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 269

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 270

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 271

Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 272

Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 273

Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 274

Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 275

Products under Investigation by Universities/Institutes, H2 2016 (Contd..10) 276

Products under Investigation by Universities/Institutes, H2 2016 (Contd..11) 277

Products under Investigation by Universities/Institutes, H2 2016 (Contd..12) 278

Products under Investigation by Universities/Institutes, H2 2016 (Contd..13) 279

Products under Investigation by Universities/Institutes, H2 2016 (Contd..14) 280

Breast Cancer – Pipeline by 3-D Matrix Ltd, H2 2016 281

Breast Cancer – Pipeline by 3-V Biosciences Inc, H2 2016 282

Breast Cancer – Pipeline by 3SBio Inc, H2 2016 283

Breast Cancer – Pipeline by 4SC AG, H2 2016 284

Breast Cancer – Pipeline by A&G Pharmaceutical Inc, H2 2016 285

Breast Cancer – Pipeline by AB Science SA, H2 2016 286

Breast Cancer – Pipeline by AbbVie Inc, H2 2016 287

Breast Cancer – Pipeline by AbGenomics International Inc, H2 2016 288

Breast Cancer – Pipeline by Acceleron Pharma Inc, H2 2016 289

Breast Cancer – Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 290

Breast Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 291

Breast Cancer – Pipeline by ADC Therapeutics Sarl, H2 2016 292

Breast Cancer – Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 293

Breast Cancer – Pipeline by Aduro BioTech Inc, H2 2016 294

Breast Cancer – Pipeline by Advanced Accelerator Applications SA, H2 2016 295

Breast Cancer – Pipeline by Advanced Cancer Therapeutics, H2 2016 296

Breast Cancer – Pipeline by Advanced Proteome Therapeutics Corp, H2 2016 297

Breast Cancer – Pipeline by Advantagene Inc, H2 2016 298

Breast Cancer – Pipeline by Advaxis Inc, H2 2016 299

Breast Cancer – Pipeline by Advenchen Laboratories LLC, H2 2016 300

Breast Cancer – Pipeline by Aegis Therapeutics LLC, H2 2016 301

Breast Cancer – Pipeline by Aeglea BioTherapeutics Inc, H2 2016 302

Breast Cancer – Pipeline by Aerpio Therapeutics Inc, H2 2016 303

Breast Cancer – Pipeline by Aeterna Zentaris Inc, H2 2016 304

Breast Cancer – Pipeline by Affichem SA, H2 2016 305

Breast Cancer – Pipeline by Agenus Inc, H2 2016 306

Breast Cancer – Pipeline by Agilvax Inc, H2 2016 307

Breast Cancer – Pipeline by Aileron Therapeutics Inc, H2 2016 308

Breast Cancer – Pipeline by Alchemia Ltd, H2 2016 309

Breast Cancer – Pipeline by Alethia Biotherapeutics Inc, H2 2016 310

Breast Cancer – Pipeline by Alissa Pharma, H2 2016 311

Breast Cancer – Pipeline by Almac Discovery Ltd, H2 2016 312

Breast Cancer – Pipeline by Alteogen Inc, H2 2016 313

Breast Cancer – Pipeline by Amarna Therapeutics BV, H2 2016 314

Breast Cancer – Pipeline by Ambrx Inc, H2 2016 315

Breast Cancer – Pipeline by American Gene Technologies International Inc, H2 2016 316

Breast Cancer – Pipeline by Amgen Inc, H2 2016 317

Breast Cancer – Pipeline by Ampio Pharmaceuticals Inc, H2 2016 318

Breast Cancer – Pipeline by Amplyx Pharmaceuticals Inc, H2 2016 319

Breast Cancer – Pipeline by Angion Biomedica Corp, H2 2016 320

Breast Cancer – Pipeline by ANP Technologies Inc, H2 2016 321

Breast Cancer – Pipeline by AntiCancer Inc, H2 2016 322

Breast Cancer – Pipeline by Antigen Express Inc, H2 2016 323

Breast Cancer – Pipeline by Antoxis Ltd, H2 2016 324

Breast Cancer – Pipeline by Aphios Corp, H2 2016 325

Breast Cancer – Pipeline by APIM Therapeutics AS, H2 2016 326

Breast Cancer – Pipeline by Aptevo Therapeutics Inc, H2 2016 327

Breast Cancer – Pipeline by Aravive Biologics Inc, H2 2016 328

Breast Cancer – Pipeline by ARMO Biosciences Inc, H2 2016 329

Breast Cancer – Pipeline by Armour Therapeutics Inc, H2 2016 330

Breast Cancer – Pipeline by Arno Therapeutics Inc, H2 2016 331

Breast Cancer – Pipeline by ArQule Inc, H2 2016 332

Breast Cancer – Pipeline by Arrien Pharmaceuticals LLC, H2 2016 333

Breast Cancer – Pipeline by Arvinas Inc, H2 2016 334

Breast Cancer – Pipeline by Asana BioSciences LLC, H2 2016 335

Breast Cancer – Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 336

Breast Cancer – Pipeline by AskAt Inc, H2 2016 337

Breast Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 338

Breast Cancer – Pipeline by Astellas Pharma Inc, H2 2016 339

Breast Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2016 340

Breast Cancer – Pipeline by AstraZeneca Plc, H2 2016 341

List of Figures

List of Figures

Number of Products under Development for Breast Cancer, H2 2016 142

Number of Products under Development for Breast Cancer – Comparative Analysis, H2 2016 143

Number of Products under Development by Companies, H2 2016 144

Number of Products under Investigation by Universities/Institutes, H2 2016 187

Comparative Analysis by Late Stage Development, H2 2016 196

Comparative Analysis by Clinical Stage Development, H2 2016 197

Comparative Analysis by Early Stage Products, H2 2016 198

Assessment by Monotherapy Products, H2 2016 738

Assessment by Combination Products, H2 2016 739

Number of Products by Top 10 Targets, H2 2016 740

Number of Products by Stage and Top 10 Targets, H2 2016 740

Number of Products by Top 10 Mechanism of Actions, H2 2016 783

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 783

Number of Products by Top 10 Routes of Administration, H2 2016 830

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 830

Number of Products by Top 10 Molecule Types, H2 2016 832

Number of Products by Stage and Top 10 Molecule Types, H2 2016 832

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports